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Ageing is a multifactorial process often characterized by a progressive decline in physiological function(s). Ageing can and is
often associated with an increased incidence of cardiovascular and renal disease. Klotho is a novel antiageing gene that encodes a
protein with multiple pleiotropic functions including an emerging role in cardiorenal disease. Mice deﬁcient for this gene display a
phenotype of premature human ageing characterized by diﬀuse vascular calciﬁcation, altered calcium/phosphate metabolism, and
shortened lifespan. Klotho is mainly expressed in the renal tubules but it also exists as circulating soluble form detectable in the
blood, with systemic eﬀects. Reduction in soluble Klotho has been associated with renal disease, hyperphosphataemia, increased
oxidative stress, endothelial dysfunction, and diﬀuse vascular calciﬁcation. Conversely, overexpression of Klotho promotes
cardiovascular-renal protection. The majority of the research on Klotho has been conducted in vitro and in animal studies but
there is emerging data from human studies which suggest that Klotho may be a modiﬁable factor involved in the pathogenesis
of cardiovascular and renal disease in at-risk populations. Further data is required to conﬁrm if this novel protein can emerge as
therapeutic tool that may be used to prevent or slow progression of cardiorenal disease.
1.Introduction
Ageing is a complex phenomenon resulting from the
interaction between genetic and environmental factors [1].
Advanced age is accompanied by higher prevalence of
cardiovascular risk factors such as diabetes, hypertension,
and chronic kidney that increase the risk of cardiovascular
morbidity and mortality. All these risk factors are associated
with endothelial dysfunction, which often precedes the
development of overt disease [2]. Endothelial dysfunction
is predominantly due to reduced availability of nitric oxide
and increased oxidative stress which also promote the
development and the progression of atherosclerosis and
vascular calciﬁcation [3]. Vascular ageing is characterized
by arteriosclerosis and calciﬁcation [4]. In conditions such
as diabetes, there is premature vascular ageing which is
associated with increased cardiovascular and renal disease
risk. Further markers of vascular calciﬁcation appear to pre-
dict cardiovascular outcomes independently of conventional
risk factors such as hyperlipidaemia, smoking, diabetes,
hypertension, and family history of disease. The mechanisms
that result in the development of vascular calciﬁcation are
complex and have been reviewed in detail recently [5].
Klotho is a gene that encodes a novel protein regulating
multiple functions, fortuitously discovered in 1997 by Kuro-
o and colleagues and named after the goddess who spins the
thread of life in Greek mythology [6].
In mice, the deletion of Klotho gene causes a phenotype
of premature human aging including vascular calciﬁcation,
altered calcium/phosphate metabolism with hyperphos-
phataemia, and shortened lifespan.
Klotho protein exists in two forms: a type I transmem-
brane protein (1014 amino acids) with a large extracellular
domain and a short intracellular portion (10 amino acids),
predominantly expressed in the renal tubules, and a circulat-
ing soluble factor detectable in blood and in lesser extent in
other biological ﬂuids [7].2 International Journal of Hypertension
Soluble Klotho is produced either by proteolytic cleavage
of the extracellular domain of the transmembrane form
(130kDa isoform) operated by the membrane-anchored
proteases ADAM10 and ADAM17 or by alternative mRNA
splicing (isoform 70kDa) [7, 8]. The systemic eﬀects of this
protein appear to be predominantly due to the circulating
form. The transmembrane protein forms a complex with
ﬁbroblast growth factor (FGF) receptors and works as an
obligatecoreceptorforFGF23,abone-derivedhormonethat
induces phosphate excretion into urine [9–11].
The fact that FGF23 requires Klotho for binding to its
receptor explains why Klotho- and FGF23-deﬁcient mice
display identical phenotype [12, 13]. The observed hyper-
phosphataemia in Klotho and FGF23-mutant mice is due
to hypervitaminosis D and increased expression/activity of
renal sodium-dependent phosphate cotransporters. Interest-
ingly, Klotho-deﬁcient mice display higher levels of FGF23,
and a low-phosphate diet reduces the levels of FGF23 and
results in a rescue of the features of premature aging [13,
14]. This suggests that FGF23 per se cannot promote a
phosphaturic eﬀect in absence of Klotho [9].
Klotho/FGF23 signalling induces phosphaturia by sup-
pressing the sodium-dependent phosphate cotransporters
type IIa (NPT2a) expressed on the brush border membrane
of renal tubular cells. Soluble Klotho has also been found
to regulate directly the phosphate transport, in the prox-
imal tubule of the kidney by deglycosylation of NaPi-2a
cotransporters [15]. The resulting reduction in number and
activity of NaPi-2a promotes phosphaturia independently
of FGF-23. Soluble Klotho also inhibits type III sodium-
dependent phosphate cotransporters (Pit1 and Pit2) which
are ubiquitously expressed and mediate phosphate uptake
[15].
HighFGF23levelsinpatientswithchronickidneydisease
are due to the declining renal clearance and also may repre-
sent a compensatory response to hyperphosphataemia [16].
Recent observational data suggest that FGF23 is asso-
ciated with and may represent an independent risk fac-
tor for cardiovascular and all-cause mortality in patients
with chronic kidney diseases stage of 4 and 5 (eGFR <
30mL/min) [17, 18].
The reduction in Klotho expression observed in chronic
kidneydiseasemaybeanimportanteventcontributingtothe
above with accumulation of FGF23 being a compensatory
mechanism to the increase of phosphate levels driven by
the primary reduction in Klotho. Recent data support this
hypothesis as changes in Klotho levels appear to precede
changes in phosphate levels, the key driver of FGF23 balance
in renal disease [19].
2. Role of Klotho inCardiovascularand
Renal Disease
Klotho expression is aﬀected by physiological and patholog-
ical factors. Renal expression of Klotho in rat is minimal
in prenatal life but increases after birth [20]. A reduction
in renal, serum, and urine levels of Klotho has been
observedwithnormalageingandindiseasescharacterisedby
Table 1: Conditions and disease states associated with reduction in
Klotho.
Disease/condition Species
Ageing Mouse/human
Diabetes Mouse
Hypertension Rat
Chronic kidney disease Mouse/human
Acute kidney injury Human
Kidney ischemia Mouse
Glomerulonephritis Mouse
premature vascular ageing such as renal disease as well as in
animal models of disease such as diabetes and hypertension
[21–24]. Table 1 summarises the conditions and disease
states associated with reduction in Klotho levels.
Conversely, there is evidence in animals that the over-
expression of soluble Klotho can reverse the ageing process
and provides cardiovascular-renal protection possibly by
inducing resistance to oxidative stress and protecting tissues
from oxidative damage [25, 26].
In this paper, we will summarize the key areas of research
on the putative role of Klotho in prevention or delay of
cardiorenal progression. We performed a Pub Med/Medline
searchforthetermsKlotho, cardiovasculardisease,andrenal
disease from 2000 to 2010 with a focus on recent mechanistic
and proof-of-concept studies evaluating the role of Klotho in
the prevention and treatment of cardiorenal disease.
3. Nephroprotective Effects of Klotho
Klotho is predominantly expressed in the renal distal tubular
cells [6]. Animal studies have showed that the nephropro-
tective eﬀects of this protein are mostly attributable to the
antioxidant properties of its soluble form [27]. As outlined
earlier, Klotho is a key mediator of phosphate balance in the
nephron.
Klotho expression is reduced in renal distal tubules,
urine, and blood of rats subjected to bilateral renal ischemia
[28].Interestingly,theinjectionofanadenovirusharbouring
the Klotho gene (which results in the release of soluble
Klotho into the circulation) or the administration of recom-
binant soluble Klotho protein prior to the induction of
the ischemic insult blunts the increase in creatinine and
attenuates the tubulointerstitial damage [28–30]. Klotho
expression is also downregulated in an animal model of
spontaneous hypertension, and the delivery of Klotho has
beenshowntopreventtheprogressionofhypertension,renal
damage, and the proteinuria [31, 32]. Several mechanistic
explanations for these observations have been proposed, and
these centre on the reduction of renal superoxide and sup-
pression of NADPH oxidase activity that is the main source
of reactive oxygen species (ROS) which are all involved in
the pathogenesis of renal disease. The observed nephro-
protective eﬀects appear to be at least in part independent
of an acute (early) eﬀect of Klotho on systemic bloodInternational Journal of Hypertension 3
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Figure 1: Putative mechanisms by which reduction in Klotho results in cardiorenal disease.
pressure. However, treatment with Klotho does prevent the
progression of spontaneous hypertension [32].
The nephroprotective eﬀects of Klotho have also been
tested in an animal model of glomerulonephritis [33]. The
transgenic overexpression of Klotho in a mouse model of
glomerulonephritis resulted in increased survival, attenuated
glomerular and tubulointerstitial changes, and reduced pro-
teinuria and blood urea nitrogen [33].
In vivo, the intraperitoneal administration of soluble
Klotho recombinant protein, immediately after the induc-
tion of unilateral ureteral obstruction, prevents the acute
renal ﬁbrosis through the inhibition of TGFβ1 signalling
[34]. Speciﬁcally Klotho binds to the type II receptor
(TGFβR2) suppressing the activation of the type I receptor
(TGFβR1) that phosphorylates Smad2/3 proteins (transcrip-
tion factors regulating the expression of TGFβ1t a r g e tg e n e s )
[34].
Studies conducted in humans have reported a reduction
of Klotho, both tissue (transmembrane) and soluble forms,
in acute and chronic kidney disease. Koh et al. examined
the kidneys of 10 patients with clinical or histological
diagnosis of chronic kidney disease and demonstrated that
the expression of Klotho protein was signiﬁcantly reduced
when compared to healthy control [35].
There are limited studies evaluating changes in serum
and urine levels of Klotho in humans; Yamazaki and his
colleagues were the ﬁrst to establish a novel assay to detect
circulating serum Klotho [24]. In 181 healthy Asian volun-
teers between 0.1 and 88 years of age, serum concentrations
ofKlothorangedfrom239to1266pg/mL.Levelswerehigher
in young subjects and lower in older adults and negatively
correlated with serum creatinine levels [24].
A reduction of Klotho levels in urine has been reported
in patients with acute kidney injury and in subjects with
chronic kidney disease [28, 36]. Hu et al. have recently found
in 39 patients with diﬀerent severity of CKD lower levels of
Klotho in urine. This decrease in urinary levels of Klotho is
early at stage 1 and correlates with the decline of eGFR [36].
Klotho may be an early clinical biomarker of acute
and chronic renal injury CKD as its diminution precedes
changes of other well-established markers/factors involved in
the progression of renal failure. However, further long-term
prospective studies are required to establish the utility/value
of Klotho as an early marker of acute and chronic renal
disease.
4.VascularProtectiveEffects of Klotho
Soluble Klotho has an important role in maintaining endo-
thelial wall homeostasis and promoting the health of the
vasculature [37–39]. In experimental models, the absence of
Klotho gene is associated with endothelial dysfunction and
diﬀuse vascular calciﬁcation [36, 38]. Recent experimental
studies have conﬁrmed that soluble Klotho may act as a
humoral factor that protects the vascular system [39].
Endothelial dysfunction results from the imbalance
betweenthereleaseofvasodilatorandvasoconstrictorfactors
and is an early step in the development and progression
of cardiovascular disease. This disrupted equilibrium is4 International Journal of Hypertension
predominantly due to the reduced bioavailability of nitric
oxide (NO) because of its inactivation by ROS [3]. NO not
only produces vasodilatation but also prevents the ather-
ogenic mechanisms by suppressing smooth muscle cell pro-
liferation and by inhibiting the expression of adhesion mol-
ecules and platelet aggregation [2].
Saito et al. demonstrated that in Klotho heterozygous
mutant mice endothelium-dependent vasodilatation in the
aortaandarteriolesinresponsetoacetylcholineisattenuated
and the excretion of urinary nitric oxide metabolites is
reduced[37].InKlothoheterozygousmutantmiceischemia-
induced angiogenesis is impaired and is accompanied by a
decreased number of endothelial progenitor cells, which are
important in the repair of damaged vessels, in the peripheral
blood [40].
Klotho gene delivery, mediated by adenoviral vector,
in a rat model of atherosclerosis, increased endothelium-
dependent NO synthesis and prevented adverse vascular
remodelling [37].
Klotho is also involved in the modulation of endothelial
inﬂammation as demonstrated in vitro by Maekawa et al. In
human umbilical vein endothelial cells (HUVECs), soluble
recombinantproteinmightsuppresstheexpressionadhesion
molecules involved in the pathogenesis of vascular disease
such as intracellular adhesion molecule-1 (ICAM-1) and
vascular cell adhesion molecule-1 (VCAM-1) [41].
Hu et al. have documented that Klotho is a direct
inhibitor of vascular smooth muscle cell (VSMC) calciﬁca-
tion. The authors showed in an elegant mouse model that
Klothodeﬁciencyisassociatedwithmoreseverecalciﬁcation,
undetectable levels of soluble Klotho, and higher serum
levels of phosphorus, whereas Klotho overexpression was
accompanied by less calciﬁcation, preserved levels of Klotho
and normal renal function [36]. In vitro, the recombinant
soluble Klotho prevented the VSMC calciﬁcation induced by
high phosphate through the inhibition of sodium-phosphate
cotransporters Pit1 and Pit2 [36]. However, whether VSMC
expresses endogenous Klotho is not known and this remains
an important area for further research. In humans, the
reduced urinary levels of Klotho in CKD might at least
in part explain associated vascular calciﬁcation, a predictor
of cardiovascular risk. As lack of soluble Klotho is an
important factor in the pathogenic mechanisms of vascular
calciﬁcation, its replacement may be a potential future thera-
peutic approach in the vascular risk management of patients
with CKD [36].
5. Conclusions
Soluble Klotho is a novel humoral factor that confers resis-
tance to oxidative stress associated with ageing and several
pathological conditions predisposing to cardiovascular-renal
damage. There is emerging evidence highlighting the essen-
tial involvement of Klotho in calcium/phosphate metab-
olism and the maintenance of vascular integrity. Figure 1
summarises the potential mechanisms by which Kotho may
aﬀord cardiorenal protection. Since the decline in soluble
Klotho levels represents a negative event occurring in the
early stages of cardiovascular-renal disease, Klotho might be
consideredasausefulbiomarkerthatpredictsatherosclerosis
and vascular calciﬁcation. Further long-term clinical studies
arerequiredtoestablishtheroleofthisexcitingnewpotential
marker and predictor of cardiorenal disease.
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